Litcius/Paper detail

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Isla S. Mackenzie, Ian Ford, George Nuki, Jesper Hallas, Christopher J. Hawkey, John Webster, Stuart H. Ralston, James Walters, Michele Robertson, Raffaele De Caterina, Evelyn Findlay, Fernando Pérez-Ruiz, John J.V. McMurray, Thomas M. MacDonald, J.N.Y. Aziz, Gary Dobson, Alex S. F. Doney, Robert Flynn, Jacqueline Furnace, J. W. Kerr Grieve, Gregory Guthrie, Diane Jamieson, Claudine G. Jennings, Sharon Kean, Lars Christian Lund, Alex McConnachie, Filippo Pigazzani, Philip L. Riches, M. HANSON, Amy Rogers, E. Douglas Rooke, John Thomson, M.A. Warren, Kirsty Wetherall, Robbie S. Wilson, C.P. Hall, A Maseri, H. A. Bird, Gordon Murray, James W. Dear, Mark C. Petrie, Michael P. MacDonald, Pardeep S. Jhund, Elizabeth A. Connolly, David J. Murphy, Narinder Paul, A G Olsson, P.T. Koskinen, A. Fuat, Alexis Foster, Wendy Saywood, R.J. Barr, Lewis McConnachie, Louis F. Wilson, L. Larsen Rasmussen, A.R. McGinnis, H Birrell, M. Keiller, I.S. Bremner, Gareth Forbes, Jennifer Dumbleton, Jonathan Rhodes, Theodore Waller

2020The Lancet342 citationsDOIOpen Access PDF

Topics & Concepts

FebuxostatMedicineGoutAllopurinolTerm (time)Prospective cohort studyOpen labelInternal medicineClinical trialPhysical therapyIntensive care medicineHyperuricemiaUric acidPhysicsQuantum mechanicsGout, Hyperuricemia, Uric AcidThyroid Disorders and TreatmentsDiet, Metabolism, and Disease